Damora Therapeutics Inc. (DMRA)
Damora Therapeutics Inc. (DMRA) Stock Price, Analysis & Data
| Bid | 22.27 |
| Market Cap | 1.91B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -262.83M |
| Beta | n/a |
| EPS (ttm) | -2.68 |
| PE Ratio (ttm) | n/a |
| Forward PE | -14.57 |
| P/B (ttm) | 4.93 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 38.69 |
| Volume | 312,069 |
| Avg. Volume (20D) | 580,572 |
| Open | 30.29 |
| Previous Close | 30.36 |
| Day's Range | 29.89 - 31.52 |
| 52-Week Range | 2.45 - 38.33 |
| Analyst | Strong Buy |
| Price Target | 45 (45.16%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN ...
Financial Performance
In 2025, Damora Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -209.84M, an increase of 878.77%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for DMRA stock is "Strong Buy". The 12-month stock price forecast is 45, which is upside of 45.16% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
